

1 **Palladium-mediated enzyme activation suggests multiphase initiation of glycogenesis**

2 Matthew K. Bilyard¹, Henry Bailey², Lluís Raich,³ Maria Gafitescu^{1†}, Takuya Machida^{1†}, Javier Iglésias-
3 Fernández,^{3,5} Seung Seo Lee^{1,6}, Christopher D. Spicer¹, Carme Rovira^{3,4}, Wyatt. W. Yue^{2*} and
4 Benjamin G. Davis^{1*}

5 ¹Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road,
6 Oxford, OX1 3TA, UK

7 ²Structural Genomics Consortium, University of Oxford, Old Road Campus Research Building,
8 Roosevelt Drive, Oxford, OX3 7DQ, UK

9 ³ Departament de Química Inorgànica i Orgànica (Secció de Química Orgànica) and Institut de
10 Química Teòrica i Computacional (IQTC), Universitat de Barcelona, Barcelona, Spain

11 ⁴ Institució Catalana de Recerca i Estudis Avançats (ICREA), Passeig Lluís Companys, 23, 08020
12 Barcelona, Spain.

13 ⁵ Current Address: Institut de Química Computacional i Catalisi and Departament de Química,
14 Universitat de Girona, Girona, Spain

15 ⁶ School of Chemistry, University of Southampton, Southampton, SO17 1BJ

16 † These authors contributed equally.

17 *e-mail: wyatt.yue@sgc.ox.ac.uk, ben.davis@chem.ox.ac.uk

18

19 Dedication: This paper is dedicated to the memory of Prof. Peter Reilly (Iowa State University), a
20 friend, mentor and colleague who is still very much missed.

21

22

23

24

25 **Biosynthesis of glycogen, the essential glucose (and hence energy) storage molecule in humans,**
26 **animals and fungi,¹ is initiated by glycosyltransferase enzyme glycogenin (GYG) (ED Figure 1).**
27 **Deficiencies in glycogen formation cause neurodegenerative and metabolic disease (ED Figure**
28 **1b).²⁻⁴ Mouse knockout⁵ and inherited human mutations⁶ of GYG impair glycogen synthesis. GYG**
29 **acts as a ‘seed core’ for the formation of the glycogen particle by catalyzing its own stepwise auto-**
30 **glucosylation to form a covalently-bound gluco-oligosaccharide chain at initiation site Tyr195. To**
31 **date, an inability to access homogeneous glycoforms of this protein, which unusually acts as both**
32 **catalyst and substrate, has precluded precise mechanistic studies. Here we show that,**
33 **unprecedented, direct access to different, homogeneously glucosylated states of GYG can be**
34 **accomplished through a palladium-mediated enzyme activation ‘shunt’ process using on-protein**
35 **C–C bond-formation. Careful mimicry of GYG intermediates recapitulates catalytic activity at**
36 **distinct stages, which in turn allows discovery of tri-phasic kinetics and substrate plasticity in**
37 **GYG’s use of sugar substrates. This reveals a tolerant but ‘proof-read’ mechanism that underlies**
38 **the precision of this vital metabolic process. This demonstration of direct, chemically-controlled**
39 **access to intermediate states of active enzymes suggests that such ligation-dependent activation**
40 **could be a powerful tool in the study of mechanism.**

41 The initial anchor point for the dendron-like structures that make up glycogen is the Tyr195
42 residue of GYG (GYG1 numbering); glycogenesis is therefore a striking example of α -linked protein
43 autoglucosylation.⁷ Prior studies have suggested GYG to be a dimeric,⁸ Mn^{2+} -dependent enzyme
44 belonging to the GT-8 family of retaining glycosyltransferases.^{9,10} GYG is – by virtue of its self-
45 modifying nature – non-identical for each glucosylation step; i.e. GYG, unlike nearly all biosynthetic
46 enzymes, is strictly *not* a catalyst since it is itself changed at each step. This leads potentially to
47 altered activity for each intermediate state and presumably to eventual inactivity once ‘buried’ in
48 glycan. This opens up the unusual possibility of distinct sub-phases and mechanisms occurring at
49 different oligosaccharide chain lengths; crystal structures suggest possible intra-monomeric and
50 inter-monomeric glucosylation modes within the GYG protein dimer.¹⁰ Whilst bespoke
51 biosynthetically-deficient expression host strains can generate a glycan-free, starting form of GYG,¹¹
52 this allows access to only one catalyst state (**Supplementary Text**). As a result, any possible
53 ‘(sub)phases’ subsequent to this starting state may be obscured if they follow faster kinetics. A lack
54 of access to homogeneous GYG catalyst states therefore restricts our current understanding.

55 We reasoned that chemical construction of pure GYG in different glucosylation states might
56 allow a strategy for direct, guided (‘shunted’) activation (and hence interrogation) of chosen
57 intermediate states (**Figure 1** and **ED Figures 1c,2a**). The unusual hybrid nature of these catalyst
58 states – part-catalyst-part-substrate – suggested a convergent (tag-and-modify¹²) construction

59 process in which the desired (glycosyl acceptor) glycan moiety would be covalently attached in one-
60 step to key catalytic site 195 (**ED Figure 1c**). We have previously demonstrated that Pd(0)-mediated
61 C–C-bond forming ligation is feasible and benign in certain biological contexts.¹³⁻¹⁷ Pd-mediated
62 approaches in biology have since been elegantly exploited by various groups.¹⁸⁻²⁰ However, GYG is a
63 testing target biomolecule on which to apply this method. Not only is site 195 in the heart of the
64 active site, but GYG is also metal-dependent, raising the possibility of inhibitory ‘poisoning’ cross-
65 competition^{21,22} by Pd at the metal co-factor site.

66 A suitable precursor GYG1 bearing a reactive ‘tag’ for Pd(0)-mediated C–C bond formation
67 was generated via site-specific unnatural amino acid incorporation,^{14,23,24} giving a variant in which
68 the *para*-hydroxy group of the natural, wild-type (wt) tyrosine residue at site 195 was exchanged for
69 an iodide atom (OH→I, GYG-Tyr195→GYG-*p*I_{Phe}195, **Figure 1**). Characterization confirmed no
70 deleterious effects on overall enzyme structure. The structure of GYG-Y195*p*I_{Phe}, determined in
71 both *apo* (2.2 Å) and Mn²⁺+UDP bound (2.4 Å) states (**Supplementary Table S1**), revealed highly
72 superimposable dimers to those in GYG-wt¹⁰ (**ED Figure 2c**). In the ligand-bound state, the *p*I_{Phe}195
73 group from one monomer is clearly visible (**ED Figure 2d**, inset), located within a partially unwound
74 helix that adopts a catalytically poised position equidistant to either active site of the dimer (**ED**
75 **Figure 2d**, red). Asymmetry at the dimer interface, consistent with previous unglucosylated GYG-wt
76 structures¹⁰, suggested likely conformational flexibility needed as GYG transitions from unconjugated
77 to differently glucosylated forms.

78 Studies on wild-type GYG (GYG-wt / GYG-Tyr195) revealed concentration-dependence of Pd
79 inhibition and hence determination of essentially benign Pd concentrations that would successfully
80 allow preservation of enzymatic activity (**ED Figure 3** and **Supplementary Note**); other cross-
81 coupling components had minimal effect. These conditions allowed successful Pd-mediated C(sp²)–
82 C(sp²) ligation of GYG-*p*I_{Phe}195 to a variety of designed, systematically-altered ‘substrate templates’
83 (**Figure 1** and **ED Figure 2a, 4**); all bore nucleophilic, hydroxyl groups as possible reaction sites for
84 auto-glucosylation (readily prepared as their corresponding C(sp²) boronic acid derivatives **1**, see
85 **Supplementary Methods**). Small amounts of side-products were also identified (**ED Figure 5**): for
86 example, unreacted GYG-*p*I_{Phe}195 or species attributable to dehalogenation¹⁷ using LC-MS analysis
87 and negative control studies (**Supplementary Methods** and **Supplementary Text**). Despite successful
88 Pd-mediated ligation, ‘simple’ glycan-mimic templates (**ED Figure 4**) provided ineffective mimicry:
89 irrespective of systematically varied nature (orientation, length or *p*K_A), none led to activation of
90 autoglucosylation. Activation of GYG requires more than just an available hydroxyl nucleophile
91 positioned in the active site. However, for more complex substrate templates displaying glucosyl
92 moieties inside GYG not only did protein LC-MS analysis reveal successful C–C ligation but also

93 concomitant activation and clear auto-glucosylation activity in the resulting ‘shunted’ intermediate
94 product GYG-Glc as well as the more advanced, chain-extended shunted states GYG-Glc-Glc and
95 GYG-Glc₆ (**Figure 2** and **Supplementary Information**). Side-products from cross-coupling (**ED Figure**
96 **5**) were inactive to autoglucosylation and thus did not interfere in the assay.

97 This chemically-generated access to shunted functionally-active intermediate states of GYG
98 along the glycogen biosynthetic pathway allowed us to uniquely probe and compare activity using
99 LC-MS-monitoring of the sugars attached over time (**Figure 2c,d**, **ED Figure 6,7** and **Supplementary**
100 **Methods**). Immediately contrasting behaviours from different states were observed. For more
101 extended GYG-Glc-Glc, two distinct glucosylation phases were apparent: rapid glucosylation from 2
102 until ~4-5 Glc total, then significantly slower catalysis thereafter (**Figure 2c,d**). Indeed, the initial step
103 (GYG-Glc-Glc→GYG-Glc-Glc-Glc) was extremely rapid; on-protein kinetic analyses conducted in
104 replicate (see **Supplementary Methods**) revealed that ~90% of starting GYG-Glc-Glc was consumed
105 within 20 seconds. In striking contrast, GYG-Glc exhibited a more gradual decline in glucosylation
106 rate with increasing oligosaccharide length (**Figure 2c,d**), consistent with a significantly slower
107 initiation sub-phase for GYG-Glc (GYG-Glc→GYG-Glc-Glc) that thus obscures the rapid phase
108 immediately following (**ED Figure 6d**). Taken together, these data suggested a triphasic mechanism,
109 in which a rapid intermediate phase is flanked by significantly slower initiation (<2 glucoses) and
110 elongation (> 4/5 glucoses) phases (**ED Figure 6d**). Notably, only through the direct ‘shunt’ formation
111 of intermediates (GYG-Glc, GYG-Glc-Glc etc) achieved through Pd-mediated ligation, was unobscured
112 analysis of each sub-phase made possible (**ED Figure 7**). Clear visualisation of this kinetic profile was
113 a consequence of our ability to both circumvent initial slow Tyr195 glucosylation and also probe
114 discrete glucosylation states immediately after this. The presence of distinct (sub)phases is
115 consistent with the proposed existence of different glucosylation mechanisms for GYG^{10,25,26}.

116 Use of ‘shunted’ intermediates GYG-Glc, GYG-Glc-Glc and GYG-Glc₆ allowed the
117 determination of initial rates that gave apparent rate constants for each associated phase of $k_{app} =$
118 0.016, 0.126 and 0.003 s⁻¹, respectively (**ED Figure 7b**). These were also compared directly with
119 kinetics determined from analysis of wild-type GYG in unglucosylated form (GYG-wt-Glc0, **ED Figure**
120 **7**). As expected, the inability to access intermediate states for GYG-wt failed to reveal the distinct
121 phases shown by our chemically ‘shunted’ system. Nonetheless, global values for turnover proved
122 consistent; we now show that one consequence of the triphasic regime is an accumulation of
123 glucosylation at the end of the fast phase 2 mechanism regime (lengths 5-6 Glc) going into the
124 slower phase 3. Taken together, this confirmed quantitative mimicry at similar activity levels and
125 highlighted the need for the chemical ‘shunted’ approach in revealing detailed mechanism.

126 Quantum mechanics/molecular mechanics (QM/MM) metadynamics^{27,28} simulations (see
127 **Supplementary Methods**) allowed further insight through detailed reconstruction of the free-energy
128 surface of reaction as a function of a few selected degrees of freedom (collective variables, CVs,
129 **Supplementary Methods**). Michaelis complexes equivalent to GYG-Glc-Glc→GYG-Glc-Glc-Glc (both
130 in wt, GYG-wt-Glc3→GYG-wt-Glc4, and shunted, GYG-Glc-Glc→GYG-Glc-Glc-Glc, form) were
131 reconstructed from the structures determined here and of those in complex with UDP-Glc and
132 cellotetraose.¹⁰ Both wild-type and shunted forms gave similar results (**ED Figure 8**), consistent with
133 kinetic parameters. The free energy surface revealed a short-lived intermediate (**ED Figure 9**) along
134 the minimum free energy pathway indicative of a front-face, 'S_Ni-like' reaction mechanism (see
135 **Supplementary Video**).^{29,30} Notably, the free energy barrier ~10 kcal/mol was very low compared
136 with typical values obtained previously for similar 'S_Ni-like' glucosyl transfer reactions (~20
137 kcal/mol³⁰). Thus, together our kinetic and QM/MM experimental data reveal unprecedentedly fast
138 glycosyl-transfer for the second sub-phase of glycogen formation. The Michaelis complex (R' in **ED**
139 **Figure 9**) exhibits a near-perfect approach between the O4'-H acceptor bond and the C1-O_p donor
140 bond to assist the departure of UDP. The resulting very short C1...O4' and H...O_p distances (3.3 and
141 2.0 Å, respectively, *cf* 3.2 and 2.5 Å in prior, representative systems³⁰) for formed bonds provide
142 excellent stabilization of charge developed at the phosphate, together with proper orientation for
143 forthcoming front-face nucleophilic attack of O4' onto C1 of Glc. The acceptor O-H in GYG thus
144 creates a direct hydrogen bond H...O_p, unlike prior systems, resulting in a more stretched sugar-
145 phosphate bond (C1-O_p) in GYG (1.58 Å *cf* 1.51 Å³⁰) with a much lower associated bond-energy (~10
146 kcal/mol *cf* ~18 kcal/mol).

147 To probe the selectivities of this multiphasic GYG mechanism, we next investigated the
148 potential of GYG to use non-glucose sugar substrates.³¹ The potential for GYG to use non-glucose
149 *acceptor* sugar moieties has not been examined due to the inability, until now, to directly access
150 requisite intermediate enzyme states and to insert into those states non-glucose sugars. GYG-Glc
151 and GYG-Glc-Glc generated by Pd-mediated ligation were capable of utilising the non-glucose *donor*
152 sugar UDP-Galactose with kinetic profiles essentially qualitatively similar to analogous auto-
153 glucosylation reactions (**Figure 3a**) thereby forming GYG-Glc-(Gal)_n and GYG-Glc-Glc-(Gal)_n. Notably,
154 however, the third kinetic (sub)phase observed for auto-glucosylation was curtailed for auto-
155 galactosylation (**ED Figure 6**). Shunted access to GYG bearing common non-glucose but naturally-
156 occurring mammalian monosaccharides D-galactose (GYG-Gal) and D-mannose (GYG-Man) (**Figure**
157 **3b** and **Supplementary Information**, using boronic acid reagents **1-Gal**, **1-Man**) revealed,
158 remarkably, that both were capable of auto-glucosylation to form both GYG-Gal-(Glc)_n etc and GYG-
159 Man-(Glc)_n etc (**Figure 3c**). Kinetic analyses of this non-glucose *acceptor* activity of GYG revealed

160 glucosylation rates for **GYG-Gal** and **GYG-Man** that are initially lower as a consequence of a
161 significantly slower initiation step / (sub)phase. In contrast to their plasticity towards glucosylation,
162 the non-glucose enzyme states **GYG-Gal** and **GYG-Man** did not catalyse auto-galactosylation to any
163 significant extent (**Supplementary Table 12**). Molecular dynamics (MD) simulations (**ED Figure 9**)
164 suggested that, strikingly, the altered configurations of non-glucose sugars, e.g. **Gal** in **GYG-Glc-Gal**
165 or **UDP-Gal**, necessitated slight reorientations but could be accommodated without significantly
166 altering the interactions at the active site with key hydroxyl-binding residues. The result is that the
167 distance of the putative nucleophile (OH-4) from the electrophilic anomeric carbon (in **UDP-Gal** or
168 **UDP-Glc**, respectively) is not greatly perturbed ($O\cdots C1$ change $< 0.5\text{\AA}$) and O–C bond formation can
169 thus, unusually for GTs, evolve essentially ‘normally’ despite such changes, reflecting this
170 experimentally observed plasticity.

171 Taken together, distinct mechanistic phases of GYG (**Figure 4**) are therefore defined not only
172 by differential rates but also different donor/acceptor tolerance. Whilst the second, rapid phase (2-
173 4/5 sugars) readily tolerates Gal-to-Gal transfer throughout (species with up to 5 sugars are quickly
174 generated from **GYG-Glc-Glc**), the first and third phases show similarities in being linked by not only
175 their slower glucosylation rates but also their apparent lower tolerance of non-glucose in both
176 acceptor and donor at the same time. A plastic and rapid second phase is thus seemingly preceded
177 by a slower step that can nonetheless be primed with unnatural sugars – immediately surprising
178 given the presumed specific role of glycogen as a glucose-storage polymer – and is followed by a
179 slower and much more selective third phase. Together these three phases appear to allow ‘priming’
180 with non-glucose sugars in the first phase (e.g. Gal, Man) followed by more rapid and more plastic
181 ‘extension’ in the second phase (with either **UDP-Glc** or **UDP-Gal**) before a third ‘refining’ phase that
182 ensures use of only glucose in the more extended portions of the inner core of glycogen.

183 From data gathered here and before,¹⁰ we speculate that these phases may reflect, in part,
184 transitions between intra-monomeric and inter-monomeric modes of glucosylation within the active
185 GYG protein dimer. From our structure of GYG-pI_{Phe195} the anchor point for the oligosaccharide
186 chain of glycogen is essentially equidistant from the two active sites in GYG dimer. Molecular
187 dynamics (MD) simulations (**ED Figure 8**) with GYG bearing Glc-oligomer chains of different lengths
188 (**GYG-Glc_n**, $n = 0-5$) and conformations (intra- / inter-monomeric) suggest that the first glucosylation
189 steps ($n = 0, 1$) are preferentially inter-monomeric. A ‘blocking loop’ inbetween the acceptor arm
190 and the active site of the same subunit hampers intra-monomeric conformations. In contrast, sugar
191 chains of subsequent steps ($n = 2, 3$) circumvent the blocking loop, allowing intramonomeric
192 conformations. A key positioning residue GYG-Asp125 binds the nucleophilic acceptor Glc terminus
193 allowing equilibration into a productive Michaelis complex and guides the OH-4 to the donor site

194 from the alpha face of UDP-Glc, ready for the front-face attack (optimal for intermediate levels of
195 GYG glucosylation). Key to this process is a striking flexibility of GYG-Tyr195, which steadily recoils
196 step-by-step by the distance of one sugar ring to accommodate acceptor **Glc_n** chains of increasing
197 lengths (**Figure 4**).

198 Together these data suggest a first inter-monomer phase where the nascent oligosaccharide
199 chain is of insufficient length to easily provide the right orientation to be processed by the active site
200 but can eventually equilibrate ('hooked' into place by Asp125) to a productive Michaelis complex
201 due to flexibility of Tyr195. In the second phase, sufficient flexibility of the oligosaccharide chain
202 allows correct orientation and a rapid intra-monomer extension, yet with low selectivity. Finally, in
203 the third 'refining' phase, extension of the nascent oligosaccharide chain past the active site of its
204 own protein monomer requires extension by the active site of another monomer in a much more
205 closely linked dimer requiring careful alignment of donor substrate (UDP-Glc only) recruitment with
206 binding of the extending chain. Eventually, this chain too processes past the point of the second
207 active site and GYG's activity ceases at a longer chain length of >12 Glc units. This presents a Glc-
208 terminated core-glycan particle ready for elaboration by Glycogen Synthase (GYS) and Glycogen
209 Branching Enzyme (GBE), respectively (**ED Figure 1**).^{1,32}

210 The plasticity of GYG raises the question of whether non-glucose sugars can ever be
211 incorporated into mature glycogen particles. Whilst natural incorporation of mannose from its most
212 abundant nucleotide GDP-mannose is not feasible owing to the known specificity of GYG for
213 pyrimidine nucleotide sugar donors,³² UDP-Gal is readily available *in vivo*. In this light, the limited
214 final kinetic phase for auto-galactosylation is consistent with a 'refining' mechanism that prevents
215 mis-formed glycogen particles due to, for example, poly-Gal incorporation (**Figure 4**). At the same
216 time, GYG's ability to utilise UDP-Gal in earlier phases may facilitate early glycogenesis during times
217 in which UDP-Glc supplies are scarce. Fascinatingly, this suggests that the core of glycogen can carry
218 priming glycans that may be non-glucose in nature. Our work here also highlights that whilst non-
219 glucose sugars might serve this role, other simpler hydroxyl-only templates fail. This, in turn,
220 suggests that this core region does not serve a role as an energy storage polymer (since it would
221 release incorrect sugars for metabolism) but instead acts to anchor glycogen to the glycogenin core
222 protein. Together, these three phases – prime-extend-refine – therefore appear to represent a
223 mechanistic solution to the exquisite evolutionary balance between the difficult-to-achieve need to
224 anchor glucose-polymer to a protein with the need to ensure precise glucose-only particle formation
225 at its outer regions.

226 The chemical ligation approach used here has shown that, whilst natural C–O Tyr195-to-
227 glucose linkages cannot be accessed via any current chemical modification approach (**ED Figure 10**),
228 Pd-mediated formation of an irreversible C–C bond can yield sufficiently similar motifs to allow
229 functional mimicry of GYG in glycogenesis. They reveal that GYG’s catalytic activity does indeed vary
230 through these intermediate states and highlight how this ‘self-modulation’ seems to be exploited by
231 nature in three phases with different function. We anticipate that this methodology may ultimately
232 be expanded to now access a wider range of precise glycogen structures, enabling study of other
233 glucosylation and associated processing steps that will shine further light on the significant and ever-
234 expanding number of glycogen-associated diseases^{1,2,4,33}.

235 More broadly, the demonstration of successful mimicry that we have achieved here by using
236 Chemistry to covalently and directly ‘bolt in’ a key residue alteration to create an intermediate
237 catalytic state highlights that new protein chemistries are becoming precise and subtle enough to
238 allow precise (e.g. ‘shunt’) mechanistic experiments that would be difficult through classical
239 biochemical means. Although strategies for chemical rescue of enzymes via unmasking of caged
240 natural residues have been elegantly explored,^{19,34,35} to our knowledge these mark rare application
241 of Pd-mediated C–C-bond-forming ligation as a mode of chemical enzyme activation. It suggests that
242 such ligation-dependent activation (here using catalytic metal Pd(0) as a ‘switch’) could be a
243 powerful tool not only in the study of mechanism but even potentially in the future ‘rescue’ of
244 deficient enzymes.

245

246 **Figure Legends**

247

248 **Figure 1 | Palladium-mediated C(sp²)-C(sp²) ligation as a strategy for mechanistic investigation of**
249 **Glycogenin.** Amber codon suppression enables “OH→I” replacement of native Tyr195 acceptor of
250 GYG-wt with an unnatural L-*p*-iodophenylalanine residue. This GYG-*p*I_{Phe}195 enzyme, which lacks a
251 native glycosyl acceptor and thus cannot undergo glucosylation, represents a suitable substrate for
252 Suzuki-Miyaura cross-coupling to a range of boronic acids sugar mimic templates, to generate
253 potentially active enzyme species that mimic defined GYG glycoforms. In this way, inactive GYG-
254 *p*I_{Phe}195 might be activated through C-C bond forming ligation allowing pre-determined, ‘shunted’
255 access to intermediate catalyst states of GYG. See **ED Figures 2,4** for templates.

256

257 **Figure 2 | Generation of homogeneously glucosylated, catalytically-active GYG glycoforms and**
258 **kinetic studies of GYG-Glc and GYG-GlcGlc.** (a) Pd-mediated C-C bond forming ligation of glucose-
259 derived boronic acid **1-Glc** to GYG-Y195*p*I_{Phe} generates in good yield the homogeneous glycoform
260 GYG-Glc, which exhibits catalytic activity, as shown by LC-MS analysis. Similar results were obtained
261 for at least 4 independent repeats. In all cases, non-glucosylated side-products present show no
262 activity in the assay. (b) Cross-coupling to **1-GlcGlc** instead enables direct, shunted access to a
263 further catalytic intermediate of GYG-Glc, GYG-GlcGlc, which also proved catalytically active. Similar
264 results were obtained for at least 5 independent repeats. In all cases, non-glucosylated side-products
265 present show no activity in the assay. (c,d) Kinetic profiles of overall glucosylation (c) and initial
266 glucosylation step as monitored through consumption of starting enzyme (d and inset) for GYG-Glc
267 and GYG-GlcGlc. Glucosylation levels and abundance of starting enzyme were determined through
268 LC-MS analysis (see also **ED Figure 6** and **Supplementary Methods**). Whilst GYG-GlcGlc exhibits a
269 marked “fast → slow” biphasic profile, these same phases, whilst necessarily present for GYG-Glc,
270 are not visible, being instead obscured by a slower initiation step. For both (c) and (d), data points
271 represent mean averages of *n* independent replicate kinetic runs; *n* = 4 (GYG-Glc) and *n* = 5 (GYG-
272 GlcGlc). Error bars are ± s.d.

273

274

275 **Figure 3 | Donor and acceptor plasticity of GYG.** (a) GYG-Glc and GYG-GlcGlc are capable of utilising
276 the unnatural donor UDP-Galactose. Kinetic profiles for overall galactosylation (left) and rate of
277 initial galactosylation step (right) are illustrated. Data points represent mean averages of *n* = 3
278 independent replicate kinetic runs for both GYG-Glc and GYG-GlcGlc galactosylation. Error bars are ±
279 s.d. (b) Generation of non-natural GYG glycosyl acceptors GYG-Gal and GYG-Man. Similar results
280 were obtained for at least 3 independent repeats. (c) Autoglucosylation activity of GYG-Man and
281 GYG-Gal, compared to GYG-Glc. Kinetic profiles analogous to those in (a), overall glucosylation (left)
282 and rate of initial glucosylation step (right) are shown. Data points represent mean averages of *n*
283 independent replicate kinetic runs; *n* = 4 (GYG-Glc) and *n* = 3 (GYG-Gal, GYG-Man). Error bars are ±
284 s.d. In all cases, non-glycosylated side-products present show no activity in the assay.

285

286 **Figure 4 | Natural and unnatural pathways of GYG catalysis further delineate triphasic mechanism**
287 **and reveal possible proofreading step.** (a) Motion of Tyr195 to accommodate acceptor substrates of
288 various lengths and conformations (intra- and inter-monomeric. Results obtained from MD

289 simulations for each Michaelis complex. Acceptor sugar units have been omitted for clarity. The
290 orange loop corresponds to the acceptor arm of the same subunit of the displayed active site (i.e.
291 intra), whereas the white loop is the acceptor arm of the opposite subunit (inter). The tyrosine
292 residue represented as transparent indicate an unstable conformation due to steric hindrance with
293 the 'blocking loop' coloured in blue. Notice that the tyrosine residue recoils one position for each
294 sugar that is attached to it. Hydrogen atoms and acceptor glucose units have been omitted for
295 clarity. **(b)** Comparison of the natural autoglucoxylation pathway [and unnatural autogalactosylation
296 pathway for various GYG substrates] reveals that, whilst the slower 1st and 3rd phases (which we
297 speculate are inter-monomer) display limited Gal-Gal transfer, this reaction readily proceeds
298 throughout the fast 2nd phase (which we speculate is intra-monomer). The consequent absence of a
299 3rd phase for autogalactosylation may function as a 'refining' step, preventing incorporation of poly-
300 Gal oligosaccharides into glycogen and thus preventing accumulation of misformed, potentially toxic,
301 glycogen particles.

302

303 **Acknowledgements**

304 This work was supported by grants from the EPSRC (DTA to CDS, MKB), MINECO (CTQ2017-85496-P
305 to CR), AGAUR (2017SGR-1189 to CR), EU Horizon 2020 programme, Marie Skłodowska-Curie
306 (67507) and the Royal Society (Wolfson Research Merit Award to BGD). We thank Gustaf Hemberg
307 for useful discussions, Prof Schultz for provision of initial pEVOL-pIPhe plasmid and BSC-CNS for
308 computer resources and technical support at *MareNostrum* (RES-QCM-2016-3-0017).

309

310 **Author Contributions**

311 MKB, SSL, CDS WWY, BGD designed the project. MKB, TM, MG carried out chemical synthesis,
312 protein modification reactions, enzymatic assays and associated analysis. HB, SSL, CDS, MKB, TM,
313 MG carried out protein expression. HB performed protein expression optimisation and
314 crystallography experiments. LR, JI-F, CR performed computational experiments. MKB, CR, WWY,
315 BGD wrote the manuscript. All authors read and commented on the manuscript.

316

317 **Competing financial interests**

318 The authors declare no competing financial interests.

319

320 **Data Availability**

321 Crystallographic data have been deposited and made available under PDB accession codes: 6EQJ
322 (apo) and 6EQL (with ligands). All raw MS data supporting Figures are given in the SI and/or is
323 available on request. All primary numerical data for graphical plots in Figures is available as
324 spreadsheets. Key data deposited in open access depository ORA-data.

325

326

327 **References**

328

- 329 1 Roach, P. J., Depaoli-Roach, A. A., Hurley, T. D. & Tagliabracci, V. S. Glycogen and its
330 metabolism: some new developments and old themes. *Biochemical J.* **441**, 763-787,
331 doi:10.1042/BJ20111416 (2012).
- 332 2 Adeva-Andany, M. M., González-Lucán, M., Donapetry-García, C., Fernández-Fernández, C. &
333 Ameneiros-Rodríguez, E. Glycogen metabolism in humans. *BBA Clinical* **5**, 85-100,
334 doi:10.1016/j.bbacli.2016.02.001 (2016).
- 335 3 Roach, P. J. Are there errors in glycogen biosynthesis and is laforin a repair enzyme? *FEBS*
336 *Lett.* **585**, 3216-3218, doi:10.1016/j.febslet.2011.09.009 (2011).
- 337 4 Zois, C. E., Favaro, E. & Harris, A. L. Glycogen metabolism in cancer. *Biochemical*
338 *Pharmacology* **92**, 3-11, doi:10.1016/j.bcp.2014.09.001 (2014).
- 339 5 Testoni, G. *et al.* Lack of Glycogenin Causes Glycogen Accumulation and Muscle Function
340 Impairment. *Cell Metab* **26**, 256-266.e254, doi:10.1016/j.cmet.2017.06.008 (2017).
- 341 6 Moslemi, A.-R. *et al.* Glycogenin-1 Deficiency and Inactivated Priming of Glycogen Synthesis.
342 *New England Journal of Medicine* **362**, 1203-1210, doi:10.1056/NEJMoa0900661 (2010).
- 343 7 Alonso, M. D., Lomako, J., Lomako, W. M. & Whelan, W. J. Tyrosine-194 of glycogenin
344 undergoes autocatalytic glucosylation but is not essential for catalytic function and activity.
345 *FEBS Lett.* **342**, 38-42 (1994).
- 346 8 Hurley, T. D., Stout, S., Miner, E., Zhou, J. & Roach, P. J. Requirements for catalysis in
347 mammalian glycogenin. *J. Biol. Chem.* **280**, 23892-23899, doi:10.1074/jbc.M502344200
348 (2005).
- 349 9 Gibbons, B. J., Roach, P. J. & Hurley, T. D. Crystal structure of the autocatalytic initiator of
350 glycogen biosynthesis, glycogenin. *J. Mol. Biol.* **319**, 463-477, doi:10.1016/S0022-
351 2836(02)00305-4 (2002).
- 352 10 Chaikuad, A. *et al.* Conformational plasticity of glycogenin and its maltosaccharide substrate
353 during glycogen biogenesis. *Proc. Natl. Acad. Sci. USA* **108**, 21028-21033,
354 doi:10.1073/pnas.1113921108 (2011).
- 355 11 Hurley, T. D., Walls, C., Bennett, J. R., Roach, P. J. & Wang, M. Direct detection of glycogenin
356 reaction products during glycogen initiation. *Biochem Biophys Res Commun.* **348**, 374-378
357 (2006).
- 358 12 Chalker, J. M., Bernardes, G. J. L. & Davis, B. G. A "Tag-and-Modify" Approach to Site-
359 Selective Protein Modification. *Accounts of Chemical Research* **44**, 730-741,
360 doi:10.1021/ar200056q (2011).
- 361 13 Chalker, J. M., Wood, C. S. C. & Davis, B. G. A convenient catalyst for aqueous and protein
362 Suzuki-Miyaura cross-coupling. *J. Am. Chem. Soc.* **131**, 16346-16347, doi:10.1021/ja907150m
363 (2009).
- 364 14 Spicer, C. D. & Davis, B. G. Palladium-mediated site-selective Suzuki-Miyaura protein
365 modification at genetically encoded aryl halides. *Chem. Commun.* **47**, 1698-1700,
366 doi:10.1039/c0cc04970k (2011).
- 367 15 Spicer, C. D., Triemer, T. & Davis, B. G. Palladium-mediated cell-surface labeling. *J. Am.*
368 *Chem. Soc.* **134**, 800-803, doi:10.1021/ja209352s (2012).
- 369 16 Spicer, C. D. & Davis, B. G. Rewriting the bacterial glycocalyx via Suzuki-Miyaura cross-
370 coupling. *Chem. Commun.* **49**, 2747-2749, doi:10.1039/c3cc38824g (2013).
- 371 17 Dumas, A. *et al.* Self-liganded Suzuki-Miyaura coupling for site-selective protein PEGylation.
372 *Angew. Chem. Intl Ed. Engl.* **52**, 3916-3921, doi:10.1002/anie.201208626 (2013).
- 373 18 Li, J. & Chen, P. R. Moving Pd-Mediated Protein Cross Coupling to Living Systems.
374 *ChemBioChem* **13**, 1728-1731, doi:10.1002/cbic.201200353 (2012).
- 375 19 Yang, M., Li, J. & Chen, P. R. Transition metal-mediated bioorthogonal protein chemistry in
376 living cells. *Chemical Society Reviews* **43**, 6511-6511, doi:10.1039/C4CS00117F (2014).

- 377 20 Muhammad, J., Kumar, M. S. & Ashraf, B. Palladium in the Chemical Synthesis and
378 Modification of Proteins. *Angewandte Chemie International Edition* **56**, 10644-10655,
379 doi:doi:10.1002/anie.201702370 (2017).
- 380 21 Boeggeman, E. & Qasba, P. K. Studies on the metal binding sites in the catalytic domain of
381 β 1,4-galactosyltransferase. *Glycobiology* **12**, 395-407, doi:10.1093/glycob/cwf045 (2002).
- 382 22 Nielsen, M. M. *et al.* Substrate and Metal Ion Promiscuity in Mannosylglycerate Synthase.
383 *Journal of Biological Chemistry* **286**, 15155-15164, doi:10.1074/jbc.M110.199844 (2011).
- 384 23 Young, T. S., Ahmad, I., Yin, J. A. & Schultz, P. G. An Enhanced System for Unnatural Amino
385 Acid Mutagenesis in *E. coli*. *J. Mol. Biol.* **395**, 361-374, doi:10.1016/j.jmb.2009.10.030 (2010).
- 386 24 Davis, L. & Chin, J. W. Designer proteins: applications of genetic code expansion in cell
387 biology. *Nat. Rev. Molecular Cell Biology* **13**, 168-182, doi:10.1038/nrm3286 (2012).
- 388 25 Issoglio, F. M., Carrizo, M. E., Romero, J. M. & Curtino, J. a. Mechanisms of monomeric and
389 dimeric glycogenin autoglucosylation. *J. Biol. Chem.* **287**, 1955-1961,
390 doi:10.1074/jbc.M111.287813 (2012).
- 391 26 Bazán, S., Issoglio, F. M., Carrizo, M. E. & Curtino, J. a. The intramolecular autoglucosylation
392 of monomeric glycogenin. *Biochem. Biophys. Res. Commun.* **371**, 328-332,
393 doi:10.1016/j.bbrc.2008.04.076 (2008).
- 394 27 Laio, A. & Parrinello, M. Escaping free-energy minima. *Proc. Natl. Acad. Sci. USA* **99**, 12562-
395 12566, doi:10.1073/pnas.202427399 (2002).
- 396 28 Ardèvol, A. & Rovira, C. Reaction Mechanisms in Carbohydrate-Active Enzymes: Glycoside
397 Hydrolases and Glycosyltransferases. Insights from ab Initio Quantum Mechanics/Molecular
398 Mechanics Dynamic Simulations. *J. Am. Chem. Soc.* **137**, 7528-7547,
399 doi:10.1021/jacs.5b01156 (2015).
- 400 29 Lee, S. S. *et al.* Mechanistic evidence for a front-side, S_Ni-type reaction in a retaining
401 glycosyltransferase. *Nat Chem Biol* **7**, 631-638, doi:10.1038/nchembio.628 (2011).
- 402 30 Ardèvol, A. & Rovira, C. The molecular mechanism of enzymatic glycosyl transfer with
403 retention of configuration: evidence for a short-lived oxocarbenium-like species. *Angew.*
404 *Chem. Int. Ed. Engl.* **50**, 10897-10901, doi:10.1002/anie.201104623 (2011).
- 405 31 Carrizo, M. E., Miozzo, M. C., Goldraij, A. & Curtino, J. A. Purification of rabbit skeletal muscle
406 proteoglycogen: Studies on the glucosyltransferase activity of polysaccharide-free and -
407 bound glycogenin. *Glycobiology* **7**, 571-578, doi:10.1093/glycob/7.4.571 (1997).
- 408 32 Alonso, M. D., Lomako, J., Lomako, W. M. & Whelan, W. J. A new look at the biogenesis of
409 glycogen. *FASEB J.* **9**, 1126-1137 (1995).
- 410 33 Ashcroft, F. M., Rohm, M., Clark, A. & Brereton, M. F. Is Type 2 Diabetes a Glycogen Storage
411 Disease of Pancreatic β Cells? *Cell Metabolism* **26**, 17-23, doi:10.1016/j.cmet.2017.05.014
412 (2017).
- 413 34 Lee, H.-M., Larson, D. R. & Lawrence, D. S. Illuminating the Chemistry of Life: Design,
414 Synthesis, and Applications of "Caged" and Related Photoresponsive Compounds. *ACS*
415 *Chemical Biology* **4**, 409-427, doi:10.1021/cb900036s (2009).
- 416 35 Li, J. *et al.* Palladium-triggered deprotection chemistry for protein activation in living cells.
417 *Nat. Chem.* **6**, 352-361, doi:10.1038/nchem.1887 (2014).

418

419

420 **ED Legend Text**

421

422 **Extended Data Figure 1: Biological and chemical methods for glycogen assembly.**

423

424 **a**, Mechanism of glycogen biosynthesis in eukaryotes. The glycosyltransferase enzyme Glycogenin
425 (GYG) catalyses its successive, stepwise autoglucosylation at Tyr195 to form a short enzyme-bound
426 maltosaccharide, which undergoes further extension and branching catalysed by Glycogen Synthase
427 (GYS) and Glycogen Branching Enzyme (GBE), respectively to form mature glycogen particles.
428 Intermediate glucosylation states of Glycogenin cannot be isolated in homogeneous form via
429 conventional biological methods, hindering precise mechanistic studies.

430 **b**, The formation of glycogen from GYG placed in the context of the entire glycogenesis pathway
431 (beginning from free glucose) and glycogenolysis pathway. A wide range of pathological conditions
432 (shown in red) are known to arise from malfunction of one of the many enzymes involved. **c**, An
433 alternative chemical method, involving site-selective ligation of sugar-mimic reagents to a GYG
434 species bearing an amino acid “tag” at the 195 site may allow direct access to defined,
435 homogeneous GYG glucosylation states corresponding to intermediates along the autoglucosylation
436 pathway. This could, in turn, enable study of GYG mechanism with increased precision, through
437 analysis of individual autoglucosylation steps.

438

439 **Extended Data Figure 2: Development of Chemically-Addressable GYG Scaffold as a Strategy for**
440 **Mechanistic Investigation.**

441

442 **a**, GYG-*p*IPhe195 enzyme, which lacks a native glycosyl acceptor and thus cannot undergo
443 glucosylation, represents a suitable substrate for Suzuki-Miyaura cross-coupling to a range of
444 boronic acids, to generate potentially active enzyme species that mimic defined GYG glycoforms. In
445 this way, inactive GYG-*p*IPhe195 might be activated through C–C bond forming ligation allowing pre-
446 determined, ‘shunted’ access to intermediate catalyst states of GYG. **b**, Expression of GYG-
447 Y195*p*IPhe in *E. coli* using a polyhistidine tag removable by TEV cleavage was confirmed by LC-MS
448 and showed structural similarity to wild-type enzyme. Similar LC-MS spectra were obtained for at
449 least 3 analogous expressions. Circular dichroism plots are mean averages of 3 successive
450 measurements of the same sample ($n = 1$). **c-d**, Overlay (**c**) and (**d**) enlarged view of Chain A acceptor
451 arm for the structures of GYG-Y195*p*IPhe (Mn^{2+} +UDP, this study) (red), GYG-Phe (Mn^{2+} +UDPG)
452 (yellow), GYG-wt (Glc₄+UDP) (blue), and GYG-wt (Glc₆+UDP) (green). Inset to **d**: $2F_o - F_c$ electron
453 density map for Y195*p*IPhe of the acceptor arm. The acceptor arm in Chain B is disordered (red-
454 dashed line) and likely adopts multiple conformations to accommodate the equivalent *p*IPhe group.
455 **e**. Evidence of dimer formation for GYG in solution. **Left**: SEC-SAXS Signal Plot. Each point (orange)
456 represents the integrated area of the ratio of the sample SAXS curve to the estimated background.
457 Each point (blue) R_g estimated from the Guinier region for each frame. **Right**: Log₁₀ intensity plot of
458 subtracted and merged SAXS frames. Cyan represents averaged buffer frames subtracted from
459 averaged sampled frames. Black represents median of the buffer frames subtracted from the
460 averaged sample frames. **Above**: Aligned, averaged and refined DAMMIN Ab initio model
461 superimposed with the dimeric GYG1 crystal structure (6eqj) using supcomb. SAXS analysis was
462 performed from 16 independent scattering measurements of one biological sample.

463

464

465 **Extended Data Figure 3: Effect of SMC reagent for autoglycosylation activity and One-pot**
466 **SMC-autoglycosylation.**

467

468 **a**, Effect of different SMC components on GYG-wt activity. Plots illustrate proportions of glycoforms
469 present before (black) and after (red) glucosylation assay, as calculated from relative peak intensities
470 of each glycoform in corresponding LC-MS spectra, and represent single experiments ($n = 1$) carried
471 out in parallel. Boronic acid and the Pd-scavenger DTT did not appear to cause enzymatic
472 inactivation in isolation. In the presence of palladium with limited Pd-removal / refolding steps –
473 either far more limited activity (Pd + DTT) or no activity (all components) was seen. This highlighted
474 that Pd was the key issue regarding GYG-wt activity. **b**: The effect of cross-coupling reaction
475 components on GYG-wt structure as shown by circular dichroism analysis. Neither DTT nor boronic
476 acid (m -CH₂OH) caused any significant alteration to secondary structure. Palladium catalyst,
477 however, caused significant alteration of secondary structure. This effect could however be avoided
478 through minimised Pd concentrations and thorough Pd-scavenging and removal (see (c)). Circular
479 dichroism plots represent mean averages of 3 measurements of the same sample ($n = 1$). **c**:
480 Demonstration of “enzyme-compatible” Pd-mediated ligation. Through minimising Pd
481 concentrations employed, and post-reaction Pd removal, cross-coupling conditions compatible with
482 retention of GYG-wt activity were developed. The plot illustrates proportions of glycoforms present
483 before (black) and after (red) glucosylation assay, as calculated from relative peak intensities of each
484 glycoform in corresponding LC-MS spectra, and represents a single experiment ($n = 1$, note however
485 that the “1- m -CH₂OH” experiment in Extended Data Figure 4 is near-identical, differing only in
486 glucosylation time). Circular dichroism additionally confirmed structural similarity of GYG-wt enzyme
487 before and after subjection to optimised cross-coupling conditions. See also **Extended Data Figure 2**
488 for more details of structural analyses by x-ray crystallography. Circular dichroism plots represent
489 mean averages of 3 measurements of the same sample ($n = 1$). **d**: One-pot SMC of GYG-Y195pI_{Phe}
490 and autoglycosylation of GYG-Glc. Autoglycosylation is greater when palladium scavenging is carried
491 out prior to glucosylation assay quenching (reaction 1) than vice versa (reaction 2). LC-MS data
492 represent single experiments ran in parallel ($n=1$). **e**: Average number of glucoses added per enzyme
493 upon treatment of GYG-wt in the presence of varying final concentrations of Pd (0, 0.1, 0.2, 0.4 mM).
494 Data is mean average of 3 independent replicates ($n = 3$), error bars are \pm s.d.

495

496

497 **Extended Data Figure 4: Cross-coupling to “simple mimics” and assessment of catalytic**
498 **activity of products.**

499

500 ‘Simple’ substrate templates were introduced using aryl boronic acids **1- o -CH₂OH**, **1- m -CH₂OH**, **1- p -**
501 **CH₂OH** (exploring different angles of nucleophile display) and **1- m -OH**, **1- p -OH** (exploring reduced
502 nucleophile length with similar angles). These proceeded with useful to high conversions
503 (**Supplementary Methods, Section 6**) to allow the direct creation of systematically-altered GYG
504 conjugates bearing substrate mimics: GYG- **o -CH₂OH**, GYG- **m -CH₂OH**, GYG- **p -CH₂OH**, GYG- **m -OH**,
505 GYG- **p -OH**. LC-MS analysis showed that none of the cross-coupled products showed

506 autoglucosylation activity (upper, detail in **Supplementary Methods, Section 6.**). Irrespective of the
507 systematically varied nature of the glycan-mimic substrate templates (orientation, length or pK_a),
508 none led to efficient mimicry of substrate moiety and hence activation of autoglucosylation. Notably,
509 also, the truncated, 'linker-only' variant GYG-allyl-OH was inactive, highlighting further the critical
510 need of an effective mimic moiety for such 'shunting'. Thus, despite successful Pd-mediated ligation,
511 these 'simple' templates provided ineffective mimicry. Identically treated GYG-wt, run in parallel as a
512 positive control in each case, showed detectable activity (lower). Bar charts are graphical
513 representations of the LC-MS data for treated GYG-wt, showing abundances of each GYG glycoform
514 before (black) and after (red) autoglucosylation assay. Bar charts are representations of single LC-MS
515 experiments (n = 1, **Supplementary Tables 13,14**).

516

517

518 **Extended Data Figure 5: Proposed species observed during cross-couplings to GYG-Y195pIPhe and**
519 **possible mechanisms responsible for their formation.**

520

521 **a**, Respectively, unreacted GYG-Y195pIPhe (in certain cases), cross-coupled product, de-iodination
522 product, and a species observed uniquely in carbohydrate couplings and proposed to result from
523 "reductive substitution" of the carbohydrate moiety (with "hydride", likely from a hydrido-palladium
524 species). **b**, Formation of cross-coupling side-products is illustrated using coupling to boronic acid **1-**
525 **Glc** as an example. The relationship of these possible mechanisms to that of productive Suzuki-
526 Miyaura cross-coupling is highlighted. The generally accepted mechanism for de-iodination (red)
527 involves from coordination of a β -hydride-containing ligand to Pd following the initial oxidative
528 addition step of cross-coupling; subsequent β -hydride elimination affords a hydrido-palladium
529 species, reductive elimination from which affords de-iodinated side-product. "Reductive
530 substitution", seen here for carbohydrate systems only (blue), could be rationalised by the well-
531 documented ability of Pd to cleave $C_{allyl}-O$ bonds, including of allylic glycosides such as GYG-**Glc**, to
532 form a π -allyl species. Quenching of the latter with the same hydrido-palladium complex as invoked
533 in de-iodination – such use of a "hydride scavenger" in Pd-catalysed de-allylation is a well-
534 documented process^{43,48,49} – would result in "reductive substitution" product, i.e. replacement of the
535 carbohydrate moiety (here, glucose) with hydride. Key: blue sphere = Glc, "Ar-I" = pIPhe195 of GYG.

536

537 **Extended Data Figure 6: Distributions of Glycoforms in Assays of GYG variants and Proposed**
538 **Triphasic Mechanism.**

539

540 **a**, Species with up to 12 sugars attached are observed during autoglucosylation of GYG-wt-0Glc after
541 900 seconds reaction time. Glc-0 is slow to decline, whilst accumulation of later glycoforms (e.g. Glc-
542 7, Glc-8) is observed. This is consistent with the slow-fast-slow profile observed for the cross-coupled
543 system, highlighting the relevance of the latter. **b**, Species with up to 13 sugars attached are
544 observed during autoglucosylation of GYG-**Glc** (left) and GYG-**GlcGlc** (right). **c**, No species with more
545 than 8 sugars is seen during autogalactosylation of the same enzymes even after 2 hours reaction
546 time. Data represent mean averages from n independent replicate kinetic assays (n = 4 for GYG-**Glc**
547 glucosylation, n = 5 for GYG-**GlcGlc** glucosylation, n = 3 for all other). Error bars are \pm s.d. **d**, Proposed
548 triphasic mechanism inferred from kinetic experiments. GYG-**GlcGlc** exhibits only two distinct phases

549 (fast → slow); the slower initiation step for GYG-Glc represents an additional first (slow) phase prior
550 to reaching the disaccharide of GYG-GlcGlc.

551

552 **Extended Data Figure 7: Kinetic Analyses and Comparison of GYG-wt-0Glc with shunted GYG-**
553 **glycomimetics.**

554

555 **a**, Overlaid kinetic profiles for GYG-wt-0Glc, GYG-Glc and GYG-GlcGlc. Data are shown as mean ±
556 s.d. from n independent replicate kinetic assays (n = 4 for GYG-Glc, n = 5 for GYG-GlcGlc, n = 3 for
557 GYG-wt-0Glc). **b**, Apparent rate constants for autoglucosylation of GYG-wt-0Glc, GYG-Glc, GYG-
558 GlcGlc and GYG-Glc₆ allowed us to re-construct, using autoglucosylation kinetic parameters of each
559 of the shunted glycomimetics (right), an autoglucosylation profile in good agreement with the GYG-
560 wt-0Glc kinetic data (left: top overlay, profile; bottom overlay, non-linear fit). Data are shown as
561 mean ± s.d. for n independent replicate kinetic assays (n = 4 for GYG-Glc, n = 5 for GYG-GlcGlc, n = 3
562 for GYG-wt-0Glc, n = 2 for GYG-Glc₆). **c**, To ensure that there were no potential artefactual catalytic
563 effects from a de-iodinated side-product in giving rise to this previously unobserved rapid phase via
564 inter-molecular glucosylation we also explored its effect when added in pure form to reactions;
565 rather than any enhancement it gave rise only to slight suppression thereby discounting this
566 possibility. Observed rates (k-values) are essentially independent of levels of GYG-Y195F, which lacks
567 native acceptor capacity, highlighting that our conclusions are not influenced by such cross-coupling
568 side products. Data are shown as mean ± s.d. for n independent replicate kinetic assays (n = 3).

569

570 **Extended Data Figure 8: Glycogenin dynamics, glycoform mimic and active site structure**
571 **considering acceptors of different length.**

572

573 **a** Root mean square fluctuation (RMSF) of the enzymatic Cα atoms. Results obtained from the MD
574 simulations of the intra “UDP-Glc + (Glc)₃-Tyr195” Michaelis complex. **b** Modeled complex of the
575 GYG glycoform mimic, in comparison with the wt complex. Blue balls represent Glc units, and the red
576 and thin rectangle represents the allyl moiety. Normalized distributions of the donor-acceptor C1-O4
577 distances are reported. Both inter and intra conformations gave similar results. **c** Structural
578 superposition of intra and inter conformations for “UDP-Glc + (Glc)_n-Tyr195” complexes, with n = 0
579 to n = 5 Glc units. The orange loop corresponds to the acceptor arm of the same subunit of the
580 active site that is displayed (i.e. intra), and the white loop is the acceptor arm of the opposite
581 subunit (inter). The protein loop colored in blue hinders the approach of short acceptors in intra
582 conformations. Specifically, the loop clashes with Tyr195 for the n = 0 (intra), causing it to move
583 away from the donor, as indicated by the black arrow. The n = 1 (intra) is also affected by the loop,
584 as reflected in the shift of the corresponding C1-O4 frequency peak. Each distribution was obtained
585 from 0.4 μs of simulation data. The maximum frequency peak for intra/inter conformations
586 correspond to 6.4/3.8 Å (n = 0), at 3.6/3.2 Å (n = 1), 3.3/3.3 Å (n = 2) and 3.2/3.2 Å (n = 3). Hydrogen
587 atoms have been omitted for clarity.

588

589

590 **Extended Data Figure 9: Glycogenin plasticity and simulations of the glucosylation reaction**
591 **mechanism.**

592

593 **a**, Modeled intra “UDP-Glc + (Glc)₂-Tyr195” complexes and normalized distribution of the C1-O4
594 distances considering donor and acceptor Gal variants. The change of Glc (blue) by Gal (yellow) in
595 the acceptor displaces the reactive hydroxyl by 0.5 Å (from 3.3 Å to 3.8 Å). The Gal modification at
596 the donor site displays alternative conformations (not shown) in which the OH-2 and OH-3
597 substituents interact with D163. Hydrogen atoms have been omitted for clarity.

598 **b**, Computed free energy landscape (FEL) for the intra “UDP-Glc + (Glc)₃-Tyr195” reaction catalyzed
599 by GYG (contour lines at 1 kcal/mol) and atomic rearrangement along the reaction pathway.
600 Hydrogen atoms have been omitted for clarity, except OH-2, OH-3 and OH-4 of the acceptor sugar,
601 the OH-2 of the donor sugar and those of the side-chain amide NH₂ of Q164. Bonds being
602 broken/formed are represented as dashed red lines (snapshots 1 and 3). **c**, Hydrogen bond
603 interactions that were restrained during the initial steps of the initial classical MD simulations. Q164,
604 interacting with the acceptor OH-3, is not shown for clarity.

605

606

607 **Extended Data Figure 10: Other methods considered for generation of GYG glycoforms.**


608

609 Illustrated here are hypothetical strategies for generating a GYG-monosaccharide conjugate based
610 on tags incorporated through amber codon suppression to ensure site-specific glycosylation; the
611 corresponding natural glycoform is shown for comparison. Subjective views on advantages of our
612 chosen strategy (Suzuki-Miyaura coupling) are highlighted, along with reasons for selection over
613 alternative approaches.



614




615

616





PLEASE SCALE by 75% TO ONE COLUMN 9 CM WIDTH





a



b

Legend:

- = Glc
- = Gal
- = Glc or Gal

Glucosylation Pathway

Galactosylation Pathway Multimer Mode

